We believe this site might serve you best:

United States

English Continue

This country code will remain if no action is taken to change it.

Don't see your country?
Promega Corporation

Cell-Based Assays for Human Embryonic Stem Cells Scientific Poster



Chad Zimprich1, James T. Davis2, April M. Weir2 and Georgyi V. Los1
1Promega Corporation, Madison, WI 53711
2Stemina Biomarker Discovery, Inc., Madison, WI 53719

Understanding in vitro cell viability and cytotoxicity in any number of model systems remains a challenging task. With recent advances in stem cell biology, it is now possible to study human embryonic stem (hES) cells and their progeny (i.e. cardiomyocytes, hepatocytes, and neurons). Currently, one of the major technical problems is growing undifferentiated hES cells as a monolayer at low numbers in a multi-well format. Combining Promega’s suite of biological assays and instrumentation with Stemina’s hES cell expertise, we can facilitate novel research to characterize the cellular and functional biology of hES cells.

Here, we report hES cell applications of Promega’s broad portfolio of homogenous, cell-based assays designed to measure viability, apoptosis, cytotoxicity, and oxidative stress. CellTiter-Glo® and Caspase-Glo® 3/7 Assays measure cell viability and apoptosis, respectively, using an easy-to-read luminescent endpoint. Promega’s MultiTox-Fluor provides an alternative approach to simultaneously measure fluorescence of both cell viability and cytotoxicity. Additionally, GSH-Glo™ can be used to measure drug responses facilitating oxidative stress, which may lead to programmed cell death.

The data presented highlights the cell-based utility of CellTiter-Glo®, Caspase-Glo®3/7, MultiTox-Fluor,  MultiTox Cytotoxicity , and GSH-Glo™ assay results when hES cells were analyzed in a 96-well format.

Document Icon Download the poster PDF (444kb)

  • Part# PS116
  • Printed in USA.

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.